profit from every $100 of sales.
$0$100
Smith & Nephew
$31.28+0.90% today
-5.1% in 1 year
1-year low $26.421-year high $36.90
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $20.95 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Smith & Nephew sold, what it kept, and what it did with the cash.
Sales went from $5.22 billion in 2022 to $6.16 billion in 2025, with $625 million of profit last year.
SalesProfit
Smith & Nephew handed back 98% of the cash it generated last year.
Buybacks $502M$330M
Free cash flow 2025$852M
Bought back its own shares$502M
Paid as dividends$330M
Cash vs. debt$557M vs. $3.3B
Smith & Nephew vs. similar companies
Smith & Nephew grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Smith & Nephew | 20.9× · Fair price | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads Smith & Nephew's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 5,215 | 5,549 | 5,810 | 6,164 | |
| 3,675 | 3,819 | 4,046 | 4,192 | |
| 634 | 620 | 860 | 857 | |
| 874 | 956 | 1,221 | 1,532 | |
| 223 | 263 | 412 | 625 | |
| 0.50 | 0.60 | 0.94 | 1.43 | |
| 70.5% | 68.8% | 69.6% | 68.0% | |
| 12.2% | 11.2% | 14.8% | 13.9% | |
| 4.3% | 4.7% | 7.1% | 10.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 9,966 | 9,987 | 10,354 | 10,457 |
| Cash | 350 | 302 | 619 | 557 |
| Total debt | 2,872 | 3,084 | 3,321 | 3,327 |
| Total liabilities | 4,707 | 4,770 | 5,089 | 5,168 |
| 5,259 | 5,217 | 5,265 | 5,289 | |
| 446 | 437 | 438 | 436 | |
| 3.2% | 4.1% | 6.1% | 8.8% | |
| 4.2% | 5.0% | 7.8% | 11.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 468 | 608 | 987 | 1,285 | |
| 358 | 427 | 381 | 433 | |
| 110 | 181 | 606 | 852 | |
| Dividends paid | 327 | 327 | 327 | 330 |
| 158 | 0 | 0 | 502 | |
| 40 | 39 | 40 | 43 |
Valuation
- 20.9×
- 14.0×
- 0.50
- 2.5×
- 2.1×
- 15.4×
- 10.4×
- 6.5%
- 4.8%
- 2.6%
Profitability
- 68.0%
- 13.9%
- 10.1%
- 25.6%
- 9.1%
- 4.8%
- 11.8%
- 6.1%
- 11.6%
- 4.8%
Growth
- +5.7%
- +42.0%
- +40.9%
- +0.3%
- −0.3%
Financial health
- 1.7×
- 0.63
- 31.8%
- 6.4×
- 2.57
- 1.25
- 0.60
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 35%of 963
Top 40%of 894
Top 38%of 632
Bottom 33%of 908
Top 16%of 991
What analysts expect
- Average price target
- $32.00
- Range
- $32.00 – $32.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 2, 2026 | 1.18 | 1.16 | +1.7% |
| Aug 5, 2025 | 0.67 | 0.86 | −21.7% |
| Feb 25, 2025 | 0.23 | 0.92 | −75.5% |
| Oct 31, 2024 | 0.25 | 0.79 | −68.8% |
| Feb 27, 2024 | 0.05 | 0.97 | −94.6% |
| Aug 3, 2023 | 0.10 | 0.73 | −86.5% |
| Feb 28, 2023 | 0.03 | 0.73 | −96.4% |
| Jul 2, 2022 | 0.10 | 0.76 | −86.7% |
2.6%of the share price, paid each year
On $1,000 invested$26a year at today's yield, before tax
+0.3%2020 to 2025
Raised1 yearin a row, in our data
Paid per share, each year
$0.61 in 2015 → $0.76 in 2025
How safe it looks
52.8% of its profit
Room to growStretchedMore than it earns: 38.7%
News
A. O. Smith expects 2026 sales up ~4% excluding China as it plans to close CPE deal in H1 2027Seeking Alpha · Oct 29, 2026International Paper gains as PE firms explore bids for DS Smith (update)Seeking Alpha · Oct 15, 2026Smith & Nephew sets $878.90 price for 2030 bond tenderSeeking Alpha · Sep 16, 2026Smith-Midland secures $2.2M contract for Newport News Navy ProjectSeeking Alpha · Sep 15, 2026Smith Micro and Consumer Cellular Bring New Senior Phone Experience to Market, Helping Seniors Age in PlaceYahoo Finance · Sep 2, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
58No pass
Benjamin Graham
61Pass
Philip Fisher
70Pass
Peter Lynch
82Pass
Joel Greenblatt
32No pass
Charlie Munger
48No pass
Terry Smith
52No pass
Questions about Smith & Nephew
Is Smith & Nephew a good stock to buy?
A solid business at a fair price. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Smith & Nephew AI analysis
What does Smith & Nephew do?
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. It is in Medical - Devices, based in Watford, United Kingdom, with 16,988 employees.
Does Smith & Nephew pay a dividend?
Yes. At today's price the dividend is 2.6% a year, about 53% of its yearly profit. In 2025 it paid out $330 million in dividends.
Is Smith & Nephew stock halal?
Yes. Smith & Nephew passes our halal screen: its business is permitted and its debt is 25% of its market value, under the 30% limit. How we check
How has Smith & Nephew stock done over the past year?
Down 5.1% over the past twelve months, to $31.28. It traded between $26.42 and $36.90 and is 15.2% below its high.
Who are Smith & Nephew's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Smith & Nephew's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.